NMPA
Administration nationale des produits médicaux (Chine)
China
Last reviewed 2026-08-05
La NMPA chinoise réglemente les dispositifs médicaux par des examens techniques du CMDE. La Chine utilise un système à trois classes basé sur le risque. Les fabricants étrangers doivent désigner un titulaire d'autorisation de mise sur le marché (MAH).
NMPA STRUCTURE AND MARKET IMPORTANCE
NMPA (formerly CFDA) is China’s national authority for medical devices, drugs, and cosmetics. Technical review of higher-risk devices is led by CMDE. China is the world’s second-largest device market, so NMPA strategy often sits beside FDA/EU MDR in multi-market launch plans. Rules evolve quickly around clinical evaluation, unique device identification, and MAH accountability.
REGISTRATION PATHWAY AT A GLANCE
Class I devices generally use filing/notification. Class II and III require registration dossiers, type testing at NMPA-recognized labs, and often clinical evidence depending on catalogue rules. Foreign manufacturers must work through a Chinese Marketing Authorization Holder (MAH) that holds the certificate and post-market duties—unlike FDA clearances that a foreign firm can hold with a US agent model.
TIMELINES AND COMMON BOTTLENECKS
Class II often takes roughly 6–12 months and Class III 12–24+ months after a complete package, with clinical trials adding years when required. Bottlenecks include incomplete Chinese-language documentation, unexpected classification differences vs FDA/EU, and testing queue times. Cross-mapping product codes early reduces rework.
POST-MARKET AND VIGILANCE
After approval, MAHs manage adverse event reporting, re-registration cycles, and manufacturing change notifications. Surveillance actions and standards updates can affect devices already on market. Global RA teams should watch NMPA notices in parallel with FDA recalls and EU FSCA signals for multi-region products.
CLASSES DE DISPOSITIFS
Class I, II, III
VOIE D'APPROBATION
NMPA Registration (CMDE review)
FONCTIONS RÉGLEMENTAIRES CLÉS
- ▸Examen technique CMDE
- ▸Système MAH (titulaire d'autorisation)
- ▸Exigences de tests nationaux
- ▸Supervision des essais cliniques
- ▸Certificats d'enregistrement NMPA
SITE OFFICIEL
https://www.nmpa.gov.cn →§ RELATED INTELLIGENCE
§ FAQ
What is NMPA in China?
The NMPA (National Medical Products Administration) is China's national regulatory authority for medical devices, drugs, and cosmetics. Formerly known as CFDA, it oversees device registration, market surveillance, and post-market safety through its technical review body CMDE (Center for Medical Device Evaluation). China is the world's second-largest medical device market.
How do I register a medical device with NMPA?
NMPA registration requires appointing a Marketing Authorization Holder (MAH) in China, completing in-country testing at a NMPA-recognized laboratory for Class II and III devices, submitting a technical dossier to CMDE for review, and obtaining a registration certificate. Foreign manufacturers cannot hold the registration directly — a Chinese MAH entity is mandatory.
What are NMPA medical device classification requirements?
China uses a three-class risk-based system. Class I (lowest risk) requires filing notification with local authorities. Class II (moderate risk) requires registration with provincial-level NMPA. Class III (highest risk) requires registration with national NMPA through CMDE review. Classification is determined by the NMPA Classification Catalogue, which may differ from FDA or EU classifications for the same device.
How long does NMPA medical device approval take?
NMPA approval timelines vary by device class. Class I notification typically takes 1–2 months. Class II registration takes 6–12 months. Class III registration takes 12–24+ months due to CMDE technical review complexity. Clinical trials, if required, can add 1–3 additional years. In-country testing alone typically requires 3–6 months.
Do foreign manufacturers need a local representative for NMPA?
Yes. Foreign manufacturers must appoint a Marketing Authorization Holder (MAH) — a Chinese legal entity responsible for the device registration, post-market surveillance, and regulatory compliance in China. The MAH holds the registration certificate and bears legal responsibility. This is one of the most significant differences from FDA registration, where foreign manufacturers can hold their own clearances through a US Agent.
MedFlux surveille les changements réglementaires, alertes de sécurité et signaux de marché de NMPA en temps réel.
SURVEILLER {abbr} GRATUITEMENT →